Navigation Links
Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific Peptides
Date:3/19/2013

>A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application. The issued patent would have a term that expires no earlier than in 2030.  The 13/472,914 Notice of Allowance has been posted on the USPTO public PAIR website. 

About Palatin Technologies

Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at http://www.palatin.com

Forward-looking Statements

Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc. such as statements about potential clinical utility of melanocortin receptor-1 peptides, whether the subject patent will issue or adequately protect against competition, the future status of pending and planned patent applications, potential clinical trial results, potential actions by regulatory agencies including the U.S. Food and Drug Administration (FDA), regulatory plans, development programs, proposed indications for melanocortin receptor-1 peptide product candidates and market potential for melanocortin receptor-1 peptide product candidates, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, unce
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Palatin Technologies Announces Last Patient Completed Treatment In Phase 2B Bremelanotide Female Sexual Dysfunction Trial
2. Patient Safety Technologies Reports Fourth Quarter And Fiscal 2012 Results
3. Medbox Acquires 50% of MedVend and its Patented Technologies
4. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2012 Financial Results
5. SafeCode Drug Technologies Acquires Breakthrough Painless Injection Technology
6. Xyntek-Antares & ESS Technologies to Unveil New Ultra Compact TaskMate(R) Robotic Case Erector / Loader with Track & Trace at Interphex 2013
7. Cylene Pharmaceuticals and TetraGene Enter Agreement for Quarfloxin and Anticancer Quadruplex Technologies
8. Ajinomoto Co., Inc. Agrees To Acquire Althea Technologies, Inc.
9. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2012 Financial Results on Tuesday, March 12, 2013
10. Particle Sciences and NETZSCH Premier Technologies Enter into Collaboration
11. Animas Development of a First-Generation Closed Loop Insulin Delivery System Progresses With Data Presented at the Advanced Technologies & Treatments for Diabetes (ATTD) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 19, 2014 You,re visiting the dentist ... cleaning when he or she says you need a ... before, you may have several questions and feel apprehensive ... to know it,s nothing to worry about. The Pennsylvania ... and alleviate any anxiety the public may have surrounding ...
(Date:12/19/2014)... , Dec. 19, 2014   Hospira, Inc. ... of injectable drugs and infusion technologies, today announced that ... Annual Healthcare Conference on Wednesday, Jan. 14, 2015, in ... scheduled to begin at 10:30 a.m. Pacific time on ... all interested parties through a live audiocast accessible via ...
(Date:12/19/2014)... , Dec. 19, 2014  Monarch America Inc. ... Kinetics Corp.) is pleased to provide this review of ... growth in 2015. "Over this past year, ... and I am extremely proud to say that Monarch ... today than it has ever been," stated Eric ...
Breaking Medicine Technology:Root Canals Have Become More Routine 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3
... HONG KONG, July 18, 2011 Data from high-risk ... due to nondeferrable, non-cardiac surgery show good short- and ... Genous Stent, according to a study published online on ... In the single-center study, patients treated with ...
... Inc. (NASDAQ: OPTR ) today announced the ... of Clostridium difficile -associated diarrhea (CDAD) in patients ... Phase 3 clinical studies, DIFICID had clinical response rates ... were non-inferior to oral vancomycin. In addition, DIFICID was ...
Cached Medicine Technology:OrbusNeich's Genous™ Stent Enables Early and Safe Discontinuation of Dual Antiplatelet Therapy in High-Risk Patients Requiring Nondeferrable, Non-Cardiac Surgery 2OrbusNeich's Genous™ Stent Enables Early and Safe Discontinuation of Dual Antiplatelet Therapy in High-Risk Patients Requiring Nondeferrable, Non-Cardiac Surgery 3Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older 2Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older 3Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older 4Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older 5
(Date:12/22/2014)... Naples, Florida (PRWEB) December 22, 2014 ... this holiday season, the gift of health and vitality. ... is offering its three top-selling anti-aging formulas in special ... with free rush delivery. , Each bottle contains ... digestion, areas that don't work as well as we ...
(Date:12/22/2014)... 2014 Xarelto Lawsuit News : ... judges has granted a request to centralize pending and ... Court, Eastern District of Louisiana. The U.S. Judicial Panel ... 12 to transfer over 50 Xarelto cases–21 lawsuits and ... Louisiana court for consolidation under U.S. District Judge Eldon ...
(Date:12/22/2014)... December 22, 2014 Christmas is days away, ... a fast and easy solution that will please: the ... be purchased from from $25 up to $350," says Kathy ... customer satisfaction and a wide array of skin care products ... and no expiration dates. , Gift delivery past shipping ...
(Date:12/22/2014)... The NLN’s 2015 Leadership ... this month. Faculty have been selected through competitive ... fast-tracked for administrative leadership roles within their academic ... Simulation Educators, featuring a curriculum uniquely devised for ... , Twenty nurse educators were chosen for ...
(Date:12/21/2014)... Recently, BambooFlooringChina.com, a famous bamboo lumber supplier, has ... and launched a bamboo flooring promotion with great discounts, ... 30, 2015. , According to the CEO of the ... available today; it has a highly distinctive grain with ... woven bamboo is made by a unique manufacturing process ...
Breaking Medicine News(10 mins):Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 3Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 4Health News:NLN Leadership Institute Announces 2015 Cohorts 2Health News:NLN Leadership Institute Announces 2015 Cohorts 3Health News:BambooFlooringChina.com Announced Its Durable Strand Woven Bamboo Flooring Collection 2
... governing the private educational institutions in the state in ... cabinet decided to adopt the new rules for the ... said here. ,The school managements will now ... prescribed and timely salaries to teaching and non-teaching staff ...
... drink and the sparkle of many a party. That apart, wine ... a health drink, known to sustain cardiovascular// health and keep age ... health, it is cheers to a copious flow of health benefits. ... wine is considered sacrosanct, alluding to the blood of Christ, which ...
... Chapel Hill suggested that low LDL values can increase ... for low density lipoprotein; the low values of LDL ... been made between LDL and cardiovascular diseases, smoking and ... a lower occurrence of heart attack and stroke than ...
... “trans fat” leaves a bad taste in the mouths ... for health, but// scientists at the University of Arkansas ... by juggling the molecular structure of soy oil. ... student Vishal Jain produced soy oil rich in conjugated ...
... are the best ways to prevent the most common types ... paediatricians.// ,Kidney stones are rarely a serious condition, ... infections. Signs and symptoms of kidney stones include intense pain ... painful urination, blood in the urine and/or cloudy urine, urinary ...
... progression of Alzheimer's disease (AD) according to a study ... is one// in a group of related steroid hormones ... published in the December 20 issue of The Journal ... testosterone loss and AD, which affects 4.5 million Americans. ...
Cached Medicine News:Health News:Celebrating Christmas With Wine – The Elixir of the God 2Health News:Celebrating Christmas With Wine – The Elixir of the God 3Health News:Low LDL Levels Lead to Parkinson's Disease 2Health News:Healthy Potato Chips: A Trans Fat Oil With Health Benefits 2Health News:Drinking Plenty of Water may Prevent Kidney Stones 2Health News:Increase Testosterone Levels To Slow Down Alzheimer’ 2
Prolactin EIA Reproductive Markers 025-BC-1037...
LH EIA Reproductive Markers 025-BC-1031 Luteinizing Hormone...
... follows the basic principle of a competitive ... an unlabeled antigen and an labelled antigen ... a specific antiserum . The amount of ... to the antibody is inversely proportional to ...
... (5-Androstene-3-0L-17-one,Androstenolone, Dehydroisoandrosterone,Transdehydroandrosterone, DHEA) is a ... mostly in its,sulfate form (DHEA-S). ... based on the competition principle ... amount of DHEA-S present in ...
Medicine Products: